VIIBRYD is not approved for use in pediatric patients. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. On the breastfed child from Viibryd or from the underlying maternal condition.Īntidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. The developmental and health benefits of breastfeeding should beĬonsidered along with the mother’s clinical need for Viibryd and any potential adverse effects On the breastfed infant, or the effects of the drug on milk production.
Of pregnancy for PPHN and drug discontinuation syndrome. Monitor neonates who were exposed to Viibryd in the third trimester Respiratory support, and tube feeding, and/or persistent pulmonary hypertension of Increased risk for neonatal complications requiring prolonged hospitalization,
Reduce Viibryd dose to original level over 1 to 2 weeks. If CYP3A4 inducers are discontinued, gradually Phenytoin, rifampin) for greater than 14 days.